Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
PTC Therapeutics OCF Yield % Related Terms
PTC Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for PTC Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BH3 vs SRRK, COGT, RYTM: OCF Yield % Comparison
For the Biotechnology subindustry, PTC Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (STU:BH3) has a OCF Yield % of -3.23 as of Jul. 15, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on PTC Therapeutics and its competitors. According to the industry distribution chart, PTC Therapeutics ranks #497 out of 1410 companies in the Biotechnology industry, placing it in the top 35.2%.
Is PTC Therapeutics' OCF Yield % too high?
PTC Therapeutics' current OCF Yield % is -3.23. Based on the distribution chart, PTC Therapeutics ranks #497 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PTC Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' OCF Yield % compare to SRRK and COGT?
According to the Biotechnology industry distribution chart, PTC Therapeutics ranks #497 out of 1410 companies for OCF Yield %. This puts PTC Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current OCF Yield % is -3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (STU:BH3) has a current OCF Yield % of -3.23. The stock's GF Value™ is €31.66, compared to a current price of €68.32 — trading 115.8% above its estimated fair value. The current OCF Yield % is -3.23. PTC Therapeutics' overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For PTC Therapeutics (STU:BH3), the current OCF Yield % is -3.23 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTC Therapeutics (STU:BH3) Overvalued in 2026?
Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued.
The current stock price of €68.32 is trading 115.8% above its estimated GF Value™ of €31.66.
Key valuation signals for STU:BH3:
OCF Yield %: -3.23
GF Value™: €31.66 vs. price of €68.32 (115.8% above fair value)
No single metric tells the full story. See the STU:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
52GF Score
Get the complete analysis for STU:BH3
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BH3 has been successfully added to your 
